The Full ASGCT 27th Annual Meeting Abstracts Collection is NOW LIVE! Click here to read the full collection.
The Gene, Cell, & RNA Therapy Landscape report from ASGCT and Citeline (formerly Informa Pharma Intelligence) is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
The fourth quarterly report of 2022 from ASGCT and Citeline (formerly Informa Pharma Intelligence) is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
Highlights from this issue include:
Hemgenix, Adstiladrin approved in the U.S. for hemophilia B and bladder cancer, respectively
Ebvallo approved for Epstein-Barr virus-positive post-transplant lymphoproliferative disease
Across 2022, the pipeline (preclinical to pre-registration) of gene, cell, and RNA therapies grew by 7%
Download the full report
May 7-11, 2024 | Baltimore, MD
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico